161796-78-7
Chemical Structure
Esomeprazole sodium
Synonym(s): (S)-Omeprazole sodium; (-)-Omeprazole sodium
- CAS No.: 161796-78-7
- Formula:C17H18N3NaO3S
- Molecular Weight:367.40
IUPAC Name: sodium (S)-5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide
InChIKey: RYXPMWYHEBGTRV-JIDHJSLPSA-N
SMILES: O=[S@](C1=NC2=CC(OC)=CC=C2N1[Na])CC3=NC=C(C)C(OC)=C3C
Biological Activity: Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active proton pump inhibitor. Esomeprazole reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H+-ATPases[4]. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Esomeprazole sodium | 99.88% | Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active proton pump inhibitor. Esomeprazole reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H+-ATPases. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Esomeprazole sodium (Standard) | ≥98% | Esomeprazole (sodium) (Standard) is the analytical standard of Esomeprazole (sodium). This product is intended for research and analytical applications. Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active proton pump inhibitor. Esomeprazole reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H+-ATPases. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Esomeprazole-d6 sodium | Esomeprazole-d6 sodium is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Wayne Goh, et al. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci. 2014;17(3):439-46. [Content Brief]
- [2]. Christina Nelson, et al. Therapeutic Efficacy of Esomeprazole in Cotton Smoke-Induced Lung Injury Model. Front Pharmacol. 2017 Jan 26;8:16. [Content Brief]
- [3]. Thomas J Johnson, et al. Esomeprazole: a clinical review. Am J Health Syst Pharm. 2002 Jul 15;59(14):1333-9. [Content Brief]
- [4]. Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330. [Content Brief]
